FIELD: biotechnology.
SUBSTANCE: disclosed are a mammal antibody or an antigen-binding fragment thereof, which bind to a canine α-receptor of interleukin-4, as well as nucleic acids coding them, expression vectors and host cells for producing antibodies. Invention also relates to the use of antibodies for treating atopic dermatitis in dogs.
EFFECT: invention provides high binding affinity to canine α-receptor IL-4 and blocking the binding of canine IL-4 and/or IL-13 with canine α-receptor IL-4.
18 cl, 4 dwg, 4 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CANINE ALPHA INTERLEUKIN-4 RECEPTOR ANTIBODIES | 2020 |
|
RU2840044C1 |
| ANTI-IL31 ANTIBODIES FOR USE IN VETERINARY SCIENCE | 2020 |
|
RU2835543C1 |
| DOG ANTIBODIES WITH MODIFIED CH-CH SEQUENCES | 2014 |
|
RU2815059C2 |
| CANINIZED ANTI-HUMAN CTLA-4 ANTIBODIES | 2020 |
|
RU2822460C2 |
| DOG ANTIBODIES WITH MODIFIED CH2-CH3 SEQUENCES | 2014 |
|
RU2801209C2 |
| ANTI-CANINE CTLA-4 ANTIBODY | 2020 |
|
RU2818586C2 |
| ANTI-IL31 ANTIBODIES FOR VETERINARY USE | 2018 |
|
RU2795485C2 |
| IL4 RECEPTOR ANTIBODIES FOR USE IN VETERINARY SCIENCE | 2019 |
|
RU2837141C2 |
| PARVOVIRUS ANTIBODIES FOR USE IN VETERINARY SCIENCE | 2020 |
|
RU2830441C2 |
| ANTIBODIES TO DOGS' PD-1 | 2014 |
|
RU2732604C2 |
